Liver Ultrasound Elastography in Non-Alcoholic Fatty Liver Disease: A State-of-the-Art Summary.
Rosanna VillaniPierluigi LupoMoris SanginetoAntonino Davide RomanoGaetano ServiddioPublished in: Diagnostics (Basel, Switzerland) (2023)
Non-alcoholic fatty liver disease (NAFLD) is a chronic disease which is currently the most common hepatic disorder affecting up to 38% of the general population with differences according to age, country, ethnicity and sex. Both genetic and acquired risk factors such as a high-calorie diet or high intake of saturated fats have been associated with obesity, diabetes and, finally, NAFLD. A liver biopsy has always been considered essential for the diagnosis of NAFLD; however, due to several limitations such as the potential occurrence of major complications, sampling variability and the poor repeatability in clinical practice, it is considered an imperfect option for the evaluation of liver fibrosis over time. For these reasons, a non-invasive assessment by serum biomarkers and the quantification of liver stiffness is becoming the new frontier in the management of patients with NAFLD and liver fibrosis. We present a state-of-the-art summary addressing the methods for the non-invasive evaluation of liver fibrosis in NAFLD patients, particularly the ultrasound-based techniques (transient elastography, ARFI techniques and strain elastography) and their optimal cut-off values for the staging of liver fibrosis.
Keyphrases
- liver fibrosis
- risk factors
- weight loss
- type diabetes
- end stage renal disease
- magnetic resonance imaging
- clinical practice
- prognostic factors
- cardiovascular disease
- insulin resistance
- metabolic syndrome
- chronic kidney disease
- ultrasound guided
- ejection fraction
- lymph node
- risk assessment
- newly diagnosed
- physical activity
- patient reported outcomes
- glycemic control
- adipose tissue
- gene expression
- computed tomography
- peritoneal dialysis
- copy number
- genome wide
- climate change